Article Information
History
- March 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Pengfei Jin1,*,
- Xiling Guo1,*,
- Wei Chen2,*,
- Shihua Ma3,
- Hongxing Pan1,
- Lianpan Dai4,
- Pan Du5,6,
- Lili Wang3,
- Lairun Jin7,
- Yin Chen1,
- Fengjuan Shi1,
- Jingxian Liu1,
- Xiaoyu Xu5,
- Yanan Zhang2,
- George F. Gao4,
- Cancan Chen2,
- Jialu Feng8,
- Jingxin Li1,8,9,† and
- Fengcai Zhu1,8,9,†
- 1NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Province Center for Disease Control and Prevention; Nanjing, P.R China
- 2Anhui Zhifei Longcom Biopharmaceutical; Hefei, P.R China
- 3Guanyun County Center for Disease Control and Prevention; Guanyun County, P.R China
- 4CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences; Beijing, P.R China
- 5Vazyme Biotech; Nanjing, P.R China
- 6Basic Medical Science School, Zhengzhou University; Zhengzhou, P.R China
- 7Southeast university; Nanjing, P.R China
- 8Nanjing Medical University; Nanjing, P.R China
- 9Institute of Global Health and Emergency Pharmacy, China Pharmaceutical University; Nanjing, P.R China
- ↵†Corresponding author: Jingxin Li, No.127 Jiangsu Road, Nanjing 21009, P.R China (jingxin42102209{at}126.com); Fengcai Zhu, No.127 Jiangsu Road, Nanjing 21009, P.R China (jszfc{at}vip.sina.com)
↵* PFJ, XLG, WC contributed equally to this work.
Posted March 01, 2022.
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial
